Literature DB >> 27881463

Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells.

Naghma Khan1, Farah Jajeh1, Mohammad Imran Khan1, Eiman Mukhtar1, Sameh M Shabana1,2, Hasan Mukhtar1.   

Abstract

Many purified compounds from dietary sources have been investigated for their anticancer activities. The main issue with most agents is their effectiveness at high doses which generally could not be delivered to humans through dietary consumption. Here, we observed that cucurbitacin B, a tetracyclic triterpenoid present in pumpkins, gourds and squashes, exhibits antiproliferative effects on human non-small cell lung cancer (NSCLC) cells at nanomolar concentrations. Treatment with cucurbitacin B (0.2-0.6 μM; 24 h) was found to result in decrease in the viability of EGFR-wild type (A549 and H1792) and EGFR-mutant lung cancer cells (H1650 and H1975) and reduction in cell-colonies but had only minimal effect on normal human bronchial epithelial cells. Treatment with cucurbitacin B also caused inhibition of PI3K/mTOR and signal transducer and activator of transcription (STAT)-3 signaling along with simultaneous activation of AMPKα levels in both EGFR-wild type and EGFR-mutant lung cancer cells. Cucurbitacin B caused specific increase in the protein and mRNA expression of sestrin-3 in EGFR-mutant lung cancer cells, but not in EGFR-wild type cells. Treatment with cucurbitacin B to sestrin-3 siRNA treated EGFR-mutant cells further amplified the decrease in cell-viability and caused more sustained G2-phase cell cycle arrest, suggesting that these effects are mediated partly through sestrin-3. We also found that sestrin-3 has a role in the induction of apoptosis by cucurbitacin B in both EGFR-wild type and EGFR-mutant lung cancer cells. These findings suggest novel mechanism by the modulation of sestrin-3 for the action of cucurbitacin B and suggest that it could be developed as an agent for therapy of NSCLC.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27881463      PMCID: PMC6075515          DOI: 10.1093/carcin/bgw124

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  62 in total

Review 1.  Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.

Authors:  Steven Grant; Liang Qiao; Paul Dent
Journal:  Front Biosci       Date:  2002-02-01

2.  Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Jeffrey Kern; David Nethery; Balazs Halmos; Patrick Ma; Afshin Dowlati
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

Review 3.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

4.  The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.

Authors:  Ahmed Aribi; Sigal Gery; Dhong Hyun Lee; Nils H Thoennissen; Gabriela B Thoennissen; Rocio Alvarez; Quoc Ho; Kunik Lee; Ngan B Doan; Kin T Chan; Melvin Toh; Jonathan W Said; H Phillip Koeffler
Journal:  Int J Cancer       Date:  2012-12-13       Impact factor: 7.396

5.  Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies.

Authors:  Jun Hee Lee; Andrei V Budanov; Eek Joong Park; Ryan Birse; Teddy E Kim; Guy A Perkins; Karen Ocorr; Mark H Ellisman; Rolf Bodmer; Ethan Bier; Michael Karin
Journal:  Science       Date:  2010-03-05       Impact factor: 47.728

Review 6.  AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.

Authors:  D Grahame Hardie
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

Review 7.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

8.  Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.

Authors:  Esther Conde; Barbara Angulo; Moying Tang; Manuel Morente; Juan Torres-Lanzas; Angel Lopez-Encuentra; Fernando Lopez-Rios; Montserrat Sanchez-Cespedes
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

9.  Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway.

Authors:  Robert A Saxton; Kevin E Knockenhauer; Rachel L Wolfson; Lynne Chantranupong; Michael E Pacold; Tim Wang; Thomas U Schwartz; David M Sabatini
Journal:  Science       Date:  2015-11-19       Impact factor: 47.728

10.  Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3.

Authors:  Jun Hee Lee; Andrei V Budanov; Saswata Talukdar; Eek Joong Park; Hae Li Park; Hwan-Woo Park; Gautam Bandyopadhyay; Ning Li; Mariam Aghajan; Insook Jang; Amber M Wolfe; Guy A Perkins; Mark H Ellisman; Ethan Bier; Miriam Scadeng; Marc Foretz; Benoit Viollet; Jerrold Olefsky; Michael Karin
Journal:  Cell Metab       Date:  2012-09-05       Impact factor: 27.287

View more
  7 in total

1.  Cucurbitacin B and cisplatin induce the cell death pathways in MB49 mouse bladder cancer model.

Authors:  Yener Kurman; Ilker Kiliccioglu; Asiye U Dikmen; Guldal Esendagli; Cenk Y Bilen; Sinan Sozen; Ece Konac
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-06

Review 2.  Use of cucurbitacins for lung cancer research and therapy.

Authors:  Min Liu; Qijia Yan; Bi Peng; Yuan Cai; Shuangshuang Zeng; Zhijie Xu; Yuanliang Yan; Zhicheng Gong
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-06       Impact factor: 3.333

Review 3.  SESTRINs: Emerging Dynamic Stress-Sensors in Metabolic and Environmental Health.

Authors:  Seung-Hyun Ro; Julianne Fay; Cesar I Cyuzuzo; Yura Jang; Naeun Lee; Hyun-Seob Song; Edward N Harris
Journal:  Front Cell Dev Biol       Date:  2020-12-03

4.  Cucurbitacin B inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways.

Authors:  Renyikun Yuan; Qiumei Fan; Xiaowei Liang; Shan Han; Jia He; Qin-Qin Wang; Hongwei Gao; Yulin Feng; Shilin Yang
Journal:  Chin Med       Date:  2022-02-19       Impact factor: 5.455

5.  Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins.

Authors:  Bijiao Zhou; Shumin Zong; Weilong Zhong; Yixuan Tian; Lumeng Wang; Qian Zhang; Renya Zhang; Lei Li; Wei Wang; Jianmin Zhao; Xin Chen; Yaju Feng; Binghui Zhai; Tao Sun; Yanrong Liu
Journal:  Oncogene       Date:  2019-11-01       Impact factor: 8.756

Review 6.  Sestrins as a Therapeutic Bridge between ROS and Autophagy in Cancer.

Authors:  Miguel Sánchez-Álvarez; Raffaele Strippoli; Massimo Donadelli; Alexandr V Bazhin; Marco Cordani
Journal:  Cancers (Basel)       Date:  2019-09-22       Impact factor: 6.639

Review 7.  Sestrin2: Its Potential Role and Regulatory Mechanism in Host Immune Response in Diseases.

Authors:  Li-Xue Wang; Xiao-Mei Zhu; Yong-Ming Yao
Journal:  Front Immunol       Date:  2019-12-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.